Simone, oncology polymath and leader

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Joe Simone was oncology’s polymath. Skilled and adept in patient care, scientific and clinical discovery, administrative leadership, education as well as mentoring to a generation of oncologists through his writings.

00003893-005
Simone with a patient at St. Jude Children’s Research Hospital in 1970. Photo courtesy of St. Jude Children’s Research Hospital.

Over the years we worked together on many shared endeavors including the National Comprehensive Cancer Network, the Huntsman Cancer Institute, and many cancer policymaking organizations. He was forever creative, insightful and astute.

But Joe’s genuine affection and respect for his colleagues and friends spilled over into everything he did.

Joe and I ran for president of ASCO in the same year. With the organization heavily weighted toward medical oncologists rather than pediatricians, that more than anything else enabled me to win.

Shortly after the election I received a handwritten letter from Joe. It said, in essence, that although he had hoped he would win, he was very pleased to see me in that role and hoped that we would have many opportunities to work together in the future.

Thirty years later, I still have that letter. Joe made a lasting impact on oncology and as well as on so many of his colleagues.

He will remain forever in the lives of so many of us.


The author is the former president, chief executive officer, and chancellor,

Fox Chase Cancer Center


Joseph V. Simone’s book, “Simone’s Maxims,” is available for download through the Cancer History Project.

Robert C. Young, MD
Former president, chief executive officer, and chancellor, Fox Chase Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

FDA has been taking a look at psychedelics as a potential treatment for psychiatric and substance abuse disorders, recently publishing a final guidance for drug sponsors conducting clinical trials of psychedelics, including psilocybin, LSD, and MDMA. 
In 1971, the National Cancer Act set the United States on a path to confront one of its most formidable public health challenges. More than five decades later, the progress is undeniable. The latest 2026 report from the American Cancer Society shows continued declines in overall cancer mortality and improvements in survival for many major cancer types. Recent advances in early detection, prevention, and treatment are saving lives.
Robert C. Young, MD
Former president, chief executive officer, and chancellor, Fox Chase Cancer Center

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login